Balance Sheet (Annual)

BSFT / BroadSoft, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 94,072 90,545 69,866 101,543 175,857 82,993
    Short Term Investments 92,749 73,075 93,664 68,923 72,531 136,428
    Accounts Receivable Net Current 47,048 48,980 66,595 81,794 108,113 121,817
    Deferred Tax Assets Net Current 12,968 3,732 4,559 14,302 - -
    Other Assets Current 4,435 10,796 12,597 12,678 13,155 17,431
    Assets Current 251,272 227,128 247,281 279,240 369,656 358,669
  Assets Noncurrent
    Deferred Tax Assets Net Noncurrent - - 16,482 10,495 1,661 7,042
    Property Plant And Equipment Net 4,221 7,361 10,110 14,363 19,481 22,626
    Long Term Investments 5,000 30,102 23,340 52,030 102,385 144,159
    Restricted Cash And Cash Equivalents Noncurrent 959 584 581 17 - -
    Finite Lived Intangible Assets Net 8,842 11,247 20,390 15,568 18,835 27,839
    Goodwill 17,276 37,529 65,192 65,303 72,275 82,758
    Other Assets Noncurrent 3,386 12,955 8,121 8,279 8,081 8,107
    Assets Noncurrent 39,684 99,778 144,216 166,055 222,718 292,531
  Assets 290,956 326,906 391,497 445,295 592,374 651,200
Liabilities And Stockholders Equity
  Liabilities Current
    Accounts Payable And Accrued Liabilities Current 14,999 15,686 14,957 21,222 28,667 33,854
    Notes And Loans Payable Current 891 555 0 - - -
    Deferred Revenue Current 55,372 49,368 71,258 87,423 106,483 97,037
    Liabilities Current 71,262 65,609 86,215 108,645 135,150 130,891
  Convertible Debt Noncurrent 81,737 86,451 91,549 97,049 188,331 201,015
  Long Term Notes And Loans 461 414 0 - - -
  Deferred Revenue Noncurrent 1,764 11,781 6,404 14,033 4,571 12,152
  Deferred Tax Liabilities Noncurrent 1,433 - 3,506 1,289 - -
  Other Liabilities Noncurrent 1,056 1,416 3,312 4,030 7,289 5,908
  Liabilities 157,713 165,671 190,986 225,046 335,341 349,966
  Commitments And Contingencies - - - - - -
  Stockholders Equity Including Portion Attributable To Noncontrolling Interest
    Preferred Stock Value - - 0 0 0 0
    Common Stock Value 271 279 283 290 291 304
    Additional Paid In Capital Common Stock 191,714 208,073 254,736 279,642 333,153 383,268
    Accumulated Other Comprehensive Income Loss Net Of Tax -2,557 -3,008 -1,525 -7,712 -13,810 -21,845
    Retained Earnings Accumulated Deficit -56,185 -44,109 -52,983 -51,971 -62,601 -60,493
    Stockholders Equity Including Portion Attributable To Noncontrolling Interest 133,243 161,235 200,511 220,249 257,033 301,234
  Liabilities And Stockholders Equity 290,956 326,906 391,497 445,295 592,374 651,200

Peers - Prepackaged Software (7372)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 11133B409